A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

20032,702 citationsJournal Articlebronze Open Access

Authors

Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.

Good health and well-being

Published in: New England Journal of Medicine

Volume 349, Issue 5, pp. 427-434

Field-Weighted Citation Impact: 153.40